NFE2L2 and non-small cell lung carcinoma: Most notably, it induces a dependence on glutaminolysis for glutamate production, a therapeutic vulnerability demonstrated in the KEAPSAKE trial evaluating the glutaminase inhibitor CB-839 in KEAP1/NRF2-mutant NSCLC (NCT04265534) [77].